Shire in drug withdrawal threat

US health officials have for the first time proposed withdrawing approval of a prescription drug for the manufacturer’s failure to complete required studies after the medicine reached the market. Shire did not conduct clinical trials to verify the suggested benefits of hypotension drug ProAmatine, the Food and Drug Administration said yesterday. The drug won approval 14 years ago and is not a big seller for Shire. Shire has 15 days to request a hearing to object.